Peptide Half-Life Explained: Accumulation, Peak, Trough and Steady State

Half-life is one of the most useful peptide terms because it explains why some compounds are discussed as daily, others as weekly, and others as short pulses. It also explains why repeated doses can accumulate even when each individual dose looks modest.

The practical math is below: what half-life means, how peak and trough work, why steady state takes time, and how to use the peptide accumulation calculator without turning a simple model into a dosing plan.

For related basics, use the peptide glossary, what are peptides, and the peptide database.

The Short Version

Concept	Plain meaning	Practical point
Half-life	The time it takes for the modeled amount to fall by half.	One half-life does not mean fully cleared.
1 half-life	About 50% remains in a simple model.	A compound can still have meaningful exposure.
5 half-lives	About 3.125% remains in a simple model.	This is often used as a rough "mostly cleared" benchmark.
Accumulation	New doses are added before prior exposure has fully decayed.	Longer half-life plus shorter intervals usually means more accumulation.
Steady state	Repeated peaks and troughs become more consistent over time.	A rough rule is about 4 to 5 half-lives, but labels and studies matter.

How Half-Life Math Works

The simple model is first-order decay. Each half-life cuts the modeled amount in half:

Time elapsed	Approximate amount remaining	How to read it
1 half-life	50%	Half the modeled amount remains.
2 half-lives	25%	Half of half remains.
3 half-lives	12.5%	The amount is lower, but not zero.
4 half-lives	6.25%	Approaching low residual exposure.
5 half-lives	3.125%	Often used as a rough mostly-cleared estimate.

This model is useful for understanding direction and timing. It is not the same as a measured blood concentration curve. Real pharmacokinetics can include absorption delays, tissue distribution, active metabolites, nonlinear behavior, renal or hepatic differences, binding proteins, and formulation effects.

Peak, Trough and Accumulation

Repeated dosing creates a pattern:

Term	Meaning	Why it matters
Peak	The modeled high point after a dose is added.	High peaks can matter for side effects, tolerability and interpretation.
Trough	The modeled low point before the next scheduled dose.	Higher troughs mean more carryover from prior doses.
Accumulation factor	How much repeated dosing raises the modeled amount compared with one isolated dose.	It rises when the dose interval is short relative to the half-life.
Steady state	The repeated pattern where peaks and troughs stabilize.	Many drugs approach this after about 4 to 5 half-lives.

Use the accumulation calculator to compare scenarios like daily, every-other-day, twice-weekly, or weekly intervals. Treat the result as a visualization tool, not a dosing instruction.

Common Peptide Half-Life Examples

These are reference values from labels, trials, or database-style summaries. They are not recommendations for use.

Peptide or medicine	Reference half-life	Practical meaning	Go deeper
Semaglutide	About 1 week	Weekly GLP-1 benchmark with long carryover.	Semaglutide database
Tirzepatide	About 5 days	Weekly dual GIP/GLP-1 agonist with meaningful accumulation.	Tirzepatide database
Retatrutide	About 6 days in early clinical research	Investigational triple agonist with weekly-trial context.	Retatrutide database
Liraglutide	About 13 hours	Older GLP-1 drug with daily dosing context.	Liraglutide database
Cagrilintide	About 7 days in research summaries	Long-acting amylin analog research area.	Cagrilintide database
Ipamorelin	Short, often summarized around hours	Short-pulse GH secretagogue context, not weekly GLP-1 context.	Ipamorelin database
Tesamorelin	Short, label data are measured in minutes	Approved GHRH analog where clinical effect is not judged by raw half-life alone.	Tesamorelin database
BPC-157	Not well characterized in humans	Do not treat forum half-life claims as established clinical pharmacokinetics.	BPC-157 database
TB-500	Not well characterized in humans	Evidence quality and product identity matter more than copied half-life claims.	TB-500 database

The pattern is the important part: weekly GLP-1-style drugs are engineered for long exposure, while many peptide fragments and secretagogues are discussed as shorter signals. Half-life is only one part of the story.

Half-Life Is Not the Same as Duration of Effect

Two compounds with similar half-lives can feel or behave differently because duration of effect depends on more than elimination:

• Absorption after injection.
• Receptor binding and downstream signaling.
• Tissue distribution.
• Active metabolites.
• Product formulation.
• Dose level and titration.
• Individual kidney, liver, body-size and tolerability differences.

This is especially important for GLP-1 drugs. A label half-life can explain why weekly dosing is possible, but clinical effect also depends on receptor pharmacology, dose escalation, appetite response, glucose state and adverse effects.

How to Use the Accumulation Calculator

Use this workflow:

Step	Input	Use the result for
1	Enter the reference half-life from a label, study or database page.	Understanding decay speed.
2	Enter the repeated dose amount and interval from the source you are analyzing.	Seeing how overlap changes the modeled curve.
3	Compare peak, trough and accumulation factor.	Learning why a long half-life schedule behaves differently from a short one.
4	Change only one variable at a time.	Keeping the comparison interpretable.

Open the peptide accumulation calculator when you want to model the curve. Use the unit converter for mg, mcg and syringe unit arithmetic, and the reconstitution calculator for concentration math.

Common Mistakes

Avoid these:

• Assuming one half-life means a peptide is gone.
• Using half-life alone to choose a dose interval.
• Comparing a label half-life to an uncited forum value.
• Treating a research-only compound like an approved drug product.
• Forgetting that long half-life compounds can still be present after missed, delayed or changed doses.
• Using accumulation math as a substitute for medical supervision.

FAQ

What does peptide half-life mean?

Half-life is the time it takes for the modeled amount of a peptide or drug to fall by half. It does not mean the compound is fully gone after one half-life.

How many half-lives until a peptide is mostly cleared?

In a simple first-order model, about 3.125% remains after five half-lives. Real pharmacokinetics can differ because absorption, distribution, metabolites and patient factors matter.

How long does it take to reach steady state?

A common pharmacokinetic rule of thumb is roughly 4 to 5 half-lives to approach steady state with repeated dosing, but product-specific data matter.

Is half-life the same as duration of effect?

No. Half-life describes decline in amount or concentration, while duration of effect depends on receptors, tissue exposure, potency and the clinical or experimental endpoint.

Can this guide tell me how often to dose a peptide?

No. Half-life can explain accumulation math, but dosing frequency must come from a product label, prescriber, pharmacist or valid research protocol.

References

1. StatPearls / NCBI Bookshelf. Pharmacokinetics.

2. Novo Nordisk. Wegovy prescribing information.

3. Eli Lilly. Zepbound prescribing information.

4. Jastreboff AM, et al. Retatrutide for obesity: a phase 2 trial. New England Journal of Medicine.

5. Novo Nordisk. Saxenda prescribing information.